- Home
- BCTX
as 12-20-2024 4:00pm EST
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
| Founded: | 2014 | Country: | Canada |
| Employees: | N/A | City: | WEST VANCOUVER |
| Market Cap: | 34.6M | IPO Year: | N/A |
| Target Price: | $15.00 | AVG Volume (30 days): | 2.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.87 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.46 - $5.97 | Next Earning Date: | 12-16-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest BriaCell Therapeutics Corp. News
BCTX Breaking Stock News: Dive into BCTX Ticker-Specific Updates for Smart Investing
Simply Wall St.
3 days ago
Insider Purchases Worth US$5.52m See Losses As BriaCell Therapeutics Market Value Drops To CA$40m
GlobeNewswire
5 days ago
BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures
GlobeNewswire
5 days ago
BriaPro Therapeutics Corp. Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures
MT Newswires
9 days ago
BriaCell Therapeutics Raises $5.55 Million in an Underwritten Offering of Share Units
GlobeNewswire
9 days ago
BriaCell Therapeutics Announces Closing of $5.5 Million Public Offering
GlobeNewswire
9 days ago
BriaCell 2024 SABCS® Poster Highlights Ability of Bria-IMT™ Regimen to Increase Cancer-Fighting Immune Cells in Metastatic Breast Cancer
GlobeNewswire
11 days ago
BriaCell Therapeutics Announces Pricing of $5.5 Million Public Offering
MT Newswires
11 days ago
BriaCell Therapeutics Plans Public Offering; Shares Plunge After Hours
Compare BCTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BCTX BriaCell Therapeutics Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.